Tirzepatide (GIP/GLP-1 Dual Receptor Agonist) – Premium Quality API
Product Overview
Tirzepatide is a drug with dual agonist effects. As a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, it can promote the secretion of first and second phase insulin and reduce plasma glucagon levels (both under glucose-dependent conditions), thereby enhancing insulin secretion, lowering blood sugar levels, and suppressing appetite in a glucose-dependent manner.
Technical Specifications & Quality Attributes
Purity (HPLC): ≥ 99.0%
Identity (MS): Confirmed by HPLC/MS
Appearance: Lyophilized white to off-white powder
Quality Control: Rigorous CQA (Critical Quality Attributes) tracking, including mass spectrometry sequencing, mass balance verification, and residual solvent control under GMP-compliant standards.
Commercial Supply & Booking Terms
Supply Capacity: Fully capable of Kilogram-scale (kg) commercial batch production.
Lead Time: Due to the rigorous synthesis cycles and strict quality control protocols required for large-scale batches, a 1-month advance pre-order is required.
Regulatory & Compliance Notice
Disclaimer: This product is an active pharmaceutical ingredient (API) / chemical intermediate intended solely for laboratory research, formulation development, or further manufacturing use. It is not intended for direct human therapeutic use or direct consumer distribution. All promotion and supply adhere strictly to international and domestic advertising laws regarding pharmaceutical raw materials.